Dear Clinician:

Immune checkpoint inhibitors (ICIs) are the most commonly used type of cancer immunotherapy. Unfortunately, these agents can cause a number of immune-related adverse events (irAEs), including rheumatologic complications.

The Rheumatology Nurses Society (RNS) and Haymarket Medical Education (HME)/myCME is designing a continuing medical education (CME)/continuing education (CE) initiative focused on the diagnosis and management of rheumatologic irAEs, in collaboration with oncologists and other members of the cancer care team. Please take a few minutes to help us customize this education by completing the survey questions below.

We thank you in advance for your invaluable feedback.